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Abstract
To examine associations between hypertensive pregnancy disorders and maternal cardiovascular disease (CVD) in later
life. We examined the associations between blood pressure (BP) in pregnancy, gestational hypertension (GH) and
preeclampsia (PE) with cardiovascular measurements 6 years after index pregnancy among 4912 women participating in
the Generation R Study, the Netherlands. BP, left ventricular mass (LV mass), aortic root diameter (AOD), left atrial
diameter, fractional shortening, and carotid-femoral pulse wave velocity (PWV). Early pregnancy systolic and diastolic BP
were associated with more adverse maternal cardiovascular measurements and a higher incidence of chronic hypertension
6 years after pregnancy. GH was associated with a higher BP, a higher PWV, a larger AOD and an increased LV mass
6 years after index pregnancy. Compared to previous normotensive pregnancies these women had a sixfold increased risk
to develop chronic hypertension after pregnancy (OR 6.6, 95% CI 4.6–9.5). Compared to women with a normotensive
pregnancy, women with PE had a higher BP and a higher risk of chronic hypertension (OR 4.5, 95% CI 2.6–7.8) at follow-
up. After adjustment for BMI at follow-up in all the analyses on GH, PE and cardiovascular measurements, effect estimates
attenuated up to 65%, but remained significant. Both GH and PE are associated with markers of adverse maternal
cardiovascular health after pregnancy with an increased risk of chronic hypertension. Women with GH and PE may be
offered long-term cardiovascular follow-up incorporated in CVD risk management guidelines.
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Introduction
Differences between men and women exist regarding age-
dependent onset, severity, symptoms and outcomes of
cardiovascular disease (CVD) [1]. Increasing evidence has
shown new cardiovascular risk factors exclusive to women
related to pregnancy. These include gestational hyperten-
sion (GH) and preeclampsia (PE) [2]. The exact mecha-
nisms by which these risk factors contribute to long term
CVD risk have not been clarified. Women with GH or PE
may exhibit the phenotype of metabolic syndrome or
impaired endothelial function during, but also directly
after, pregnancy which is also seen in later life [2, 3]. These
include family history of diabetes mellitus, pregravid dia-
betes mellitus, a high total cholesterol/high-density
lipoprotein cholesterol ratio ([ 5), overweight and obesity,
and elevated blood pressure status [3]. Exposure of women
with this constitutional predisposition to the cardiovascular
challenges of pregnancy may induce transient clinical
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disease that subsides after pregnancy (GH or PE) but is
likely to re-emerge later in life as CVD [4, 5]. On the other
hand it is also plausible that products of the dysfunctional
placenta in hypertensive pregnancy disorders permanently
compromise maternal cardiovasculature with long-lasting
effects on cardiovascular health [6, 7]. In this respect
pathophysiological studies may help to identify individuals
after pregnancy with subclinical CVD as they might
compose a target population for possible interventions
before clinical signs and symptoms are evident. The aim of
this study was to assess associations of maternal gestational
blood pressure (BP) and hypertensive pregnancy disorders
with cardiovascular outcomes 6 years after delivery.
Methods
This study is embedded in the Generation R Study, a
population-based cohort study [8]. The study protocol
conforms to the ethical guidelines of the 1964 Declaration
of Helsinki and its later amendments. The Medical Ethical
Committee of the Erasmus Medical Centre Rotterdam
approved the study and written consent was obtained from
all participants. 5439 women with live born infants pro-
vided consent for postnatal analysis. We excluded women
with missing or incomplete information on hypertensive
pregnancy disorders (n = 110) or with known chronic
hypertension before initial enrolment during pregnancy
(n = 90). Also, women with cardiac abnormalities
(n = 21), twin pregnancies (n = 34) and women being
pregnant during their follow-up visit at the research centre
(n = 257) or with missing data on medication use at fol-
low-up (n = 15) were excluded, leaving 4912 participants
for the analyses (Supplementary Information S1).
BP was measured in early pregnancy (median
13.2 weeks gestation, 90% range [10.6–16.9]), mid-preg-
nancy (median 20.5 weeks gestation, 90% range
[19.1–22.4]) and late pregnancy (median 30.2 weeks ges-
tation, 90% range [29.1–31.9]) and 6 years after delivery
(90% range 5.7–7.2 years) with a validated automated
digital oscillometric sphygmomanometer (OMRON
Healthcare Europe B.V., Hoofddorp, the Netherlands) [9].
BP was measured in a research setting by trained research
assistants wearing normal clothing (no white coats). Sub-
sequently, mean arterial pressure (MAP) was derived. The
presence of doctor diagnosed GH or PE was retrieved from
hospital charts and was determined on the basis of the
former 2001 criteria described by the International Society
for the Study of Hypertension in Pregnancy [10, 11].
Information on chronic hypertension before onset of
pregnancy was obtained through a questionnaire during
pregnancy which was cross-checked with information from
the original medical records and the Dutch obstetric
database. Chronic hypertension at follow-up 6 years after
pregnancy was defined as women using anti-hypertensive
medication and/or having, in two subsequent readings, but
at one single visit, a systolic BP above 140 mmHg or a
diastolic BP above 90 mmHg. The value of two BP read-
ings over a 5 min interval were documented for each par-
ticipant. If women were having a systolic
BP[ 140 mmHg or diastolic BP[ 90 mmHg in the first
reading and also had a systolic BP[ 140 mmHg or dias-
tolic BP[ 90 mmHg in the second reading we included
them in the hypertension group. We are aware that inter-
national guidelines recommend ambulatory BP monitoring
to define or confirm clinical diagnosis of hypertension.
However ambulatory BP monitoring was not available.
Instead we also performed a sensitivity analyses in which
we labelled women as chronic hypertensive, only if they
used BP medication at follow-up.
Data on cardiovascular outcomes were collected 6 years
after index pregnancy at our research centre (range
4.9–7.0 years). Two-dimensional M-mode echocardio-
graphic measurements were performed using the ATL-
Philips Model HDI 5000 (Seattle, WA, USA) or the Logiq
E9 (GE Medical Systems, Wauwatosa, WI, USA) devices.
Aortic root diameter (AOD[sinus of Valsalva]) and frac-
tional shortening (FS) were measured. Left ventricular
mass (LV mass) was computed according to Devereux
et al. [12]. Arterial stiffness was assessed by carotid-
femoral pulse wave velocity (PWV) using an automatic
non-invasive, validated device (Complior; Artech Medi-
cal, Pantin, France). The distance between the recording
sites at the carotid (proximal) and femoral (distal) artery
was measured.
During pregnancy maternal height (cm) and weight (kg)
were measured and body mass index (BMI) (kg/m2) was
calculated. Identical measurements were obtained 6 years
after index pregnancy. Pre-pregnancy BMI was established
at enrolment through a questionnaire. Pre-pregnancy
weight was highly correlated with the measured early
pregnancy weight.
Information on maternal age, educational level, ethnic-
ity, gravidity, self-reported pre-pregnancy weight, folic
acid supplementation, smoking, pre-pregnancy history of
chronic hypertension was available from questionnaires
administered during index pregnancy. Information about
gestational age at birth, birth weight and placental weight
was obtained from medical records. Six years after index
pregnancy we obtained information on subsequent preg-
nancies in between the index pregnancy and follow-up,
anti-hypertensive medication use and educational level
through questionnaires. Regarding anti-hypertensive med-
ication use at follow-up, information on ATC-codes was
not available.
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Statistical analysis
First, we performed a non-response analysis (Supplemen-
tary Information S2). Second, missing values were imputed
using the multiple imputations procedure with five impu-
tations and these datasets were analysed together. Third,
differences in maternal characteristics were compared
between women with hypertensive pregnancy disorders
and those with normotensive pregnancies using Student’s
t test, Mann–Whitney U test and Chi square test. Fourth,
we used regression models to explore the combined effects
of maternal BP in early and late pregnancy on vascular and
cardiac outcomes, and chronic hypertension. In these
analyses we divided maternal BP in early and late preg-
nancy into equal tertiles. We also performed conditional
regression analyses to identify the independent associations
of early, mid- and late pregnancy maternal BP, taking into
account for their correlations, with vascular and cardiac
outcomes and chronic hypertension. We constructed new
systolic and diastolic BP variables, which are statistically
independent from each other, by using standardized
residuals obtained from linear regression models of
maternal systolic and diastolic BP regressed on prior cor-
responding BP measurements (see for more details Sup-
plementary Information S3) [13]. Fifth, using linear
regression models, associations between women with GH
or PE and women with a normotensive pregnancy and
vascular and cardiac outcomes were assessed. These
included; (1) basic model, adjusted for maternal age and
visit interval; (2) confounder model, which in addition to
model (1) included ethnicity, educational level, smoking,
gravidity at follow-up, child’s sex; (3) BMI model, which
included BMI at follow-up in addition to model (2). In the
BMI model we observed whether changes in the effect
estimates occurred after additional adjustment for BMI at
follow-up. The difference between the effect estimates
from model (2) and the effect estimates after adjustment for
BMI was expressed as percentage change. The percentage
change was calculated by the formula: 100 9 (effect esti-
mateBMI - effect estimateconfounder)/(effect estimatecon-
founder - 1). A 95% confidence interval for the percentage
change of the effect estimate was calculated using a
bootstrap method with 1000 resamplings [14, 15]. Using a
similar approach multiple logistic regression models were
used to examine the associations between hypertensive
pregnancy disorders and normotensive pregnancies, and
chronic hypertension at follow-up. Lastly, we carried out a
sensitivity analysis by repeating the logistic regression
analysis and defining chronic hypertension only on the
basis of anti-hypertensive medication use at follow-up.
Statistical analyses were performed using the Statistical
Package for the Social Sciences version 21.0 for Windows
(SPSS Inc, Chicago, IL, USA) and with R version 3.0.0
(libraries rmeta and metafor; The R foundation for Statis-
tical Computing).
Results
Table 1 shows maternal characteristics during index preg-
nancy and at follow-up. Women with a hypertensive
pregnancy disorder had a higher BMI before and after the
index pregnancy. They were also more often pregnant with
their first child during the index pregnancy.
In Fig. 1 we presented the combined associations of
maternal systolic and diastolic BP with cardiovascular
outcomes and the risk of hypertension 6 years after preg-
nancy. As compared to women with a systolic or diastolic
BP in the lowest tertiles during early and late pregnancy,
those with a BP in the highest tertiles in early and late
pregnancy had a higher systolic and diastolic BP, a higher
MAP, a higher FS, a higher AOD, a higher LV mass and a
higher risk of chronic hypertension 6 years after index
pregnancy (all P values\ 0.05 in confounder model).
Additionally, in the conditional analysis, which are
presented in Supplementary Information S4 and S5, the
independent associations of early, mid- and late pregnancy
systolic and diastolic BP with cardiovascular outcomes and
hypertension 6 years after pregnancy are shown. Early
pregnancy systolic and diastolic BP were associated with
BP, MAP, PWV, FS, AOD, LV mass and chronic hyper-
tension 6 years after index pregnancy (all P values\ 0.05
in confounder model).
The associations of early pregnancy BP appeared more
strongly related to cardiovascular outcomes at follow-up
than associations of mid- and late pregnancy BP.
The associations between hypertensive pregnancy dis-
orders and vascular, cardiac outcomes and the risk of
chronic hypertension at follow-up are presented in
Tables 2 and 3.
Compared to women with a previous normotensive
pregnancy, GH was strongly associated with both vascular
and cardiac outcomes and the risk of chronic hypertension.
Women with a history of GH had a 10.8 mmHg higher
systolic BP (95% Confidence Interval (CI) 9.1–12.6), a
8.7 mmHg higher diastolic BP (95% CI 7.3–10.1), 0.22 m/
s higher PWV (95% CI 0.03–0.40), a 0.90 mm larger AOD
(95% CI 0.49–1.32) and a 12.03 g larger LV mass (95% CI
7.36–16.71) at follow-up. These women also had a sixfold
higher risk to develop chronic hypertension six after index
pregnancy (OR 6.6, 95% CI 4.6–9.5). Additional adjust-
ment for BMI at follow-up showed a large attenuation of
the effect estimates, especially in AOD and LV mass (total
percentage change 54.9 and 65.18, respectively). However,
these effect estimates remained significant. Sensitivity
Hypertensive disorders of pregnancy and subsequent maternal cardiovascular health
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Table 1 Baseline characteristics by hypertensive pregnancy disorder (N = 4912)
Normotensive pregnancies
(n = 4612)
GH
(n = 205)
PE
(n = 95)
Maternal characteristics (pregnancy)
Age at intake (years) 30.3 (5.1) 30.7 (4.9) 29.6 (5.3)
Height (cm) 167 (7.5) 168 (7.3)a 166 (7.5)c
Pre-pregnancy Body Mass Index (kg/m2) 22.7 (18.8–31.6) 25.2 (19.9–38.1)a 24.2 (19.2–38.9)b
Education, Higher (%) 42.5 44.9 32.6b
Ethnicity, European (%) 58.3 74.6a 55.8c
Gravidity at intake, Primigravida (%) 46.5 64.4a 69.5b
Smoking during pregnancy (%) 23.7 28.3 20.0c
Early pregnancy blood pressure (mmHg)
Systolic (mmHg) 115 (12) 125 (13)a 121 (14)b,c
Diastolic (mmHg) 68 (9) 76 (11)a 74 (10)b
Mid-pregnancy blood pressure (mmHg)
Systolic (mmHg) 116 (12) 127 (13)a 122 (14)b,c
Diastolic (mmHg) 67 (9) 76 (10)a 75 (90)b
Late pregnancy blood pressure (mmHg)
Systolic (mmHg) 118 (12) 130 (13)a 128 (12)b
Diastolic (mmHg) 69 (9) 79 (9)a 79 (10)b
Birth characteristics
Gestational age birth (weeks) 40.1 (37.1–42.1) 40.0 (37.1–42.0) 38.3 (31.2–41.1)b,c
Birth weight (g) 3438.6 (532.3) 3375.4 (593.6) 2823.2 (833.2)b,c
Male sex (%) 50.2 47.8 45.3
Maternal characteristics (follow-up)
No subsequent pregnancies (%) 6.9 12.2a 16.8b
Body Mass Index (kg/m2) 24.6 (19.7–35.2) 27.6 (21.2–43.4)a 27.5 (20.0–43.8)b
Systolic blood pressure (mmHg) 119 (12) 130 (18)a 126 (15)b
Diastolic blood pressure (mmHg) 70 (10) 79 (13)a 78 (12)b
Mean arterial pressure (mmHg) 85 (73–104) 94 (78–125)a 92 (74–118)b
Pulse wave velocity (m/s) 7.6 (1.1) 7.8 (1.2)a 7.6 (1.1)
Fractional shortening (%) 36.9 (4.9) 37.5 (4.7) 37.3 (5.4)
Aortic root diameter (mm) 27.7 (2.8) 28.7 (2.9)a 27.9 (3.0)c
Left ventricular mass (g) 130.0 (30.9) 143.1 (34.6)a 133.0 (33.3)c
End diastolic left ventricular diameter (mm) 48.3 (4.0) 49.5 (4.1)a 48.7 (4.4)c
End diastolic left ventricular posterior wall thickness (mm) 8.0 (1.0) 8.4 (1.4)a 8.1 (1.4)
End diastolic interventricular septum thickness (mm) 8.1 (1.3) 8.4 (1.4)a 8.0 (1.4)
Anti-hypertensive medication (%) 1.2 6.3a 6.3b
Hypertension (%)d 4.9 23.4a 17.9b
Values represent means (SD), medians (90% range), or percentages. Measurements were performed in early pregnancy (median 13.2 weeks
gestation, 90% range [10.6–16.9]), mid-pregnancy (median 20.5 weeks gestation, 90% range [19.1–22.4]) and late pregnancy (median
30.2 weeks gestation, 90% range [29.1–31.9]) and 6 years after delivery (90% range 5.7–7.2 years)
Differences in subject characteristics between groups were assessed using Student’s t test or Mann–Whitney U test for continuous variables and
Chi square test for proportions
aNormotensive pregnancies versus GH with P value\ 0.05
bNormotensive pregnancies versus PE with P value\ 0.05
cGH versus PE with P value\ 0.05
dDefined as women using anti-hypertensive medication and/or having, in two subsequent readings, a systolic or diastolic blood pressure above
140 or 90 mmHg, respectively
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analyses, in which chronic hypertension was defined only
on the basis of anti-hypertensive medication use at follow-
up, showed similar results (Supplementary Information
S6). Compared to women with a previous normotensive
pregnancy, women with a history of PE had higher systolic
and diastolic BP at follow-up (6.3 mmHg; 95% CI 3.9–8.8,
and 6.8 mmHg; 95% CI 4.8–8.8, respectively). A history of
PE was associated with a higher risk of chronic hyperten-
sion at follow-up (OR 4.5, 95% CI 2.6–7.8). Additional
adjustment for BMI at follow-up showed that these asso-
ciations attenuated by approximately 25%. Sensitivity
analyses, in which chronic hypertension was defined only
on the basis of anti-hypertensive medication use at follow-
up, showed similar results (Supplementary Information
S6). Cardiac outcomes were not associated with PE.
Discussion
Main findings
Women with a history of hypertensive pregnancy disorders
exhibit a more unfavourable cardiovascular health after
pregnancy compared to women with a previous nor-
motensive pregnancy. Already 6 years after index preg-
nancy the prevalence of chronic hypertension shows an
increased risk in both women with a history of GH or PE.
The results further demonstrate that especially early preg-
nancy BP is strongly associated with the diagnosis chronic
hypertension 6 years after pregnancy. Even though these
results are strongly influenced by BMI at follow-up, effect
estimates remained significant.
Strengths and limitations
Strengths are the prospective data collection and large
sample size. Complete information on pregnancies and
pregnancy disorders that occurred in the years after the
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Fig. 1 Combined associations of maternal early and late pregnancy
blood pressure measures with cardiovascular outcomes (a–c) and the
risk of hypertension (d) 6 years after pregnancy (n = 3551). Effect
estimates or odds ratios (95% Confidence Interval) are from
multivariable linear or logistic regression models, respectively.
Results are from multiple imputed data. Women using anti-hyper-
tensive medication at follow-up are excluded from regression analysis
with cardiovascular outcomes (a,b,c) (n = 52). Hypertension (d) is
defined as women using anti-hypertensive medication at follow-up
and/or having, in two subsequent blood pressure readings, a systolic
or diastolic blood pressure above 140 or 90 mmHg, respectively.
Models are adjusted for maternal age at intake, visit interval,
ethnicity, educational level, smoking, subsequent pregnancies
between index and follow-up, and child’s sex
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index pregnancy was not available. Instead we used gra-
vidity at follow-up to account for pregnancies in between
the index pregnancy and the follow-up measurement after
6 years. BP at study intake during pregnancy was higher in
women with a history of GH than in women remaining
normotensive throughout pregnancy. Pregnancy is associ-
ated with a physiologic decrease of BP which might sug-
gest that non-random misclassification of the diagnosis
chronic hypertension occurred in our study. Nevertheless,
we think this is unlikely because information on chronic
hypertension was cross-checked between multiple sources
(maternal questionnaire in pregnancy and information from
the original medical records and the Dutch obstetric data-
base). Finally, we are aware of the fact that our approach to
define chronic hypertension at follow-up might be subop-
timal as 1) we defined chronic hypertension based upon BP
Table 2 Associations of hypertensive pregnancy disorders with cardiovascular outcomes measured 6 years after pregnancy (n = 4837)
Outcome Normotensive
pregnancy
n = 4556
GH PE
n = 192
Difference (95% CI)
% Change (95% CI) n = 89
Difference (95% CI)
% Change (95% CI)
Systolic blood pressure (mmHg)
Basic model Reference 10.9 (9.1, 12.7)** 6.4 (3.9, 8.9)**
Confounder model Reference 10.8 (9.1, 12.6)** 6.3 (3.9, 8.8)**
BMI model Reference 8.6 (6.8, 10.3)** - 21.22 (- 24.57, - 18.29)** 4.4 (2.0, 6.8)** - 28.90 (- 38.89,
- 21.30)**
Diastolic blood pressure (mmHg)
Basic model Reference 8.4 (7.0, 9.8)** 6.9 (4.9, 8.9)**
Confounder model Reference 8.7 (7.3, 10.1)** 6.8 (4.8, 8.8)**
BMI model Reference 6.7 (5.4, 8.1)** - 22.48 (- 25.40, - 19.44)** 5.1 (3.3, 7.0)** - 23.08 (- 29.78,
- 17.59)**
Mean arterial pressure (mmHg)
Basic model Reference 9.2 (7.8, 10.6)** 6.7 (4.7, 8.7)**
Confounder model Reference 9.4 (8.0, 10.8)** 6.6 (4.6, 8.6)**
BMI model Reference 7.3 (6.0, 8.7)** - 21.99 (- 24.96, - 19.18)** 4.9 (3.0, 6.8)** - 24.94 (- 31.88,
- 18.97)**
Pulse wave velocity (m/s)
Basic model Reference 0.20 (0.01, 0.39)* 0.04 (- 0.22, 0.30)
Confounder model Reference 0.22 (0.03, 0.40)* 0.04 (- 0.23, 0.30)
BMI model Reference 0.20 (0.01, 0.38)* - 7.98 (- 19.19, - 1.04)* 0.02 (- 0.24, 0.29) NA
Fractional shortening (%)
Basic model Reference 0.36 (- 0.38, 1.09) 0.22 (- 0.85, 1.28)
Confounder model Reference 0.37 (- 0.37, 1.11) 0.19 (- 0.87, 1.26)
BMI model Reference 0.25 (- 0.49, 0.99) NA 0.07 (- 1.00, 1.14) NA
Aortic root diameter (mm)
Basic model Reference 1.01 (0.59, 1.43)** 0.24 (- 0.37, 0.85)
Confounder model Reference 0.90 (0.49, 1.32)** 0.26 (- 0.34, 0.87)
BMI model Reference 0.46 (0.05, 0.87)* - 54.9 (- 70.75, - 44.29)** - 0.10 (- 0.69, 0.50) NA
Left ventricular mass (g)
Basic model Reference 13.29 (8.59, 17.98)** 3.46 (- 3.39, 10.31)
Confounder model Reference 12.03 (7.36, 16.71)** 3.93 (- 2.89, 10.75)
BMI model Reference 4.77 (0.45, 9.10)* - 65.18 (- 78.08, - 55.65)** - 3.15 (- 9.43, 3.13) NA
Values are regression coefficients or % change (95% CI) and are based on linear regression models. % change represents the change in effect
estimates after adjustment for BMI at follow-up with corresponding 95% CI. Estimates are from multiple imputed data
Basic model Adjusted for maternal age at intake and visit interval; Confounder model basic model and additionally adjusted for ethnicity,
educational level, smoking, subsequent pregnancies between index and follow-up, and child’s sex; BMI model confounder model and addi-
tionally adjusted for BMI at follow-up
Women using anti-hypertensive medication at follow-up were excluded from these analyses (n = 75)
*P\ 0.05; **P\ 0.01
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measurements at one point in time at the 6 years follow-up
visit (i.e. transient hypertension) and 2) international
guidelines recommend that ambulatory BP monitoring
should be used to define or confirm clinical diagnosis of
hypertension because of prevalence of white coat hyper-
tension. Transient hypertension is an established risk factor
(i.e. early form) of chronic hypertension [16, 17]. Unfor-
tunately, ambulatory BP monitoring was not available.
Besides, BP was measured in a research setting by trained
research assistants wearing normal clothing (i.e. no white
coats). We also performed a sensitivity analyses in which
we labelled women as chronic hypertensive, only if they
used BP medication at follow-up. These analyses showed
similar results (Supplementary Material S6).
Interpretation
Studies show that hypertensive pregnancy disorders are
associated with a woman’s risk of CVD [2]. This provides
opportunities to identify women at risk early in their lives
when it may be possible to alter their risk trajectory. It has
been shown that measures of arterial stiffness and left
ventricular function are increased during pregnancy among
women with hypertensive pregnancy disorders [18, 19].
Arterial stiffness and left ventricular function are thought
to be independent predictors of chronic hypertension and
CVD. Also aortic root dilatation may be secondary to
hypertension [18, 20, 21]. Franz et al. [22] showed dif-
ferences in PWV after index pregnancy among former
early, but not late, onset PE women. Likewise, Ghossein-
Doha et al. [23] showed increased left ventricular mass
indices and decreased cardiac diastolic function among a
population of mainly severe (early onset) PE postpartum as
proxy for hypertension. We observed increased PWV
6 years after index pregnancy among women with a history
of GH. Similarly, women with a history of GH had an
increased LV mass, a larger AOD, a higher BP and a higher
risk of chronic hypertension. Interestingly, no differences
were seen when comparing these cardiovascular measure-
ments between women with PE and normotensive women,
with the exception of an increased risk of chronic hyper-
tension. Regrettably, GH has only rarely been included in
postpartum research and despite evidence that differences
in CVD risk exist between women with severe early-onset
PE, mild late-onset PE and GH, most studies do not dif-
ferentiate between the subgroups of hypertensive preg-
nancy disorders. One large longitudinal study which
differentiated between (mild) PE and GH found that both
GH and PE were associated with greater CVD risk factors.
However after controlling for various confounders, results
for PE were not significant anymore [24]. In a study by
Wikstro¨m et al. [25] the risk of developing ischaemic heart
disease was higher in women with severe PE compared
with GH and mild PE [25, 26]. This was similar to results
reported by Lykke et al. [27]. Women with mild PE had a
four-fold higher risk of chronic hypertension. However,
this risk increased up to sixfold in women with a history of
GH and severe PE, respectively [25–27]. Similar patterns
in mean BP, usage of anti-hypertensive medication and
chronic hypertension were reported by Verbeek et al. [26]
Table 3 Associations of hypertensive pregnancy disorders with the risk of hypertension 6 years after pregnancy (n = 4912)
Outcome Normotensive
pregnancy
GH PE
n % n = 4612 n % n = 205
Odds ratio
(95% CI)
% Change
(95% CI)
n % n = 95
Odds ratio
(95% CI)
% Change
(95% CI)
Hypertensiona 228 4.9 48 23.4 17 17.9
Basic model Reference 5.8 (4.1–8.3)** 4.4 (2.6–7.6)**
Confounder
model
Reference 6.6 (4.6–9.5)** 4.5 (2.6–7.8)**
BMI model Reference 4.7 (3.2–6.9)** - 34.15
(- 38.57,
- 29.83)**
3.5 (1.9–6.2)** - 28.66
(- 37.18,
- 20.48)**
Values are odds ratios or % change in odds ratio (95% CI) and are based on logistic regression models. % change represents the change in odds
ratios after adjustment for BMI at follow-up with corresponding 95% CI. Estimates are from multiple imputed data
Basic model Adjusted for maternal age at intake and visit interval; Confounder model basic model and additionally adjusted for ethnicity,
educational level, smoking, subsequent pregnancies between index and follow-up, and child’s sex; BMI model confounder model and addi-
tionally adjusted for BMI at follow-up
*P\ 0.05; **P\ 0.01
aDefined as women using anti-hypertensive medication at follow-up and/or having, in two subsequent readings, a systolic or diastolic blood
pressure above 140 or 90 mmHg, respectively
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with the highest incidence of chronic hypertension in
severe PE followed by GH and finally mild PE. In our
study the majority of preeclamptic women had mild PE
(92%) with only eight women suffering from severe PE.
These results strengthen our findings on GH showing that
not only severe PE women exhibit an increased risk of
CVD but also that women with GH are at increased risk of
an adverse cardiovascular health profile after pregnancy.
However, the results could also indicate that, for women
with GH, this phenotype already existed prior to the index
pregnancy. Women with GH should in either case not be
excluded from (secondary) preventive interventions. A
meta-analysis found that lifestyle interventions may alter
cardiovascular risk after a history of PE up to 13% with
relatively simple intervention measures [28]. These may
include exercise, dietary counseling and support for
smoking cessation assistance.
Causal pathways relating hypertensive pregnancy dis-
orders to chronic hypertension and CVD are unclear. One
hypothesis focuses on common risk factors including
among others obesity, chronic hypertension and genetic
constitution [29]. Both PE and atherosclerosis arise from
vascular inflammation with endothelial dysfunction. It has
been also been hypothesized that hypertensive pregnancy
disorders worsen pre-existing subclinical CVD risk factors
already present before index pregnancy or even induce de
novo risk [29]. A large population-based study showed that
most CVD risk factors remain higher after PE following
adjustment for pre-pregnancy values [30]. It is possible that
products of the dysfunctional placenta in PE could per-
manently compromise maternal cardiovasculature [28]. A
study demonstrated that increased sensitivity to infused
Angiotensin II exists in the postpartum state in women with
a history of new-onset hypertension in pregnancy and that
this increased sensitivity to Angiotensin II is present in the
vasculature and in the adrenal glands, with a suggestion of
sFlt-1 responsiveness.[31] This study also showed that
women with a history of new-onset hypertension in preg-
nancy were unable to modulate a response to infused
Angiotensin II on the basis of salt intake. They suggested a
dysregulation of the renin-angiotensin system.[31] Another
study suggested persistence of left ventricular geometrical
changes that herald the development of chronic hyperten-
sion [23]. In our study we observed significant associations
regarding early pregnancy BP and all cardiac and vascular
outcomes and the risk of chronic hypertension. Also the
combined associations of maternal BP during early and late
pregnancy were consistently associated with vascular,
cardiac and hypertensive outcomes at follow-up. These
findings may corroborate those of prior research supporting
the theory that hypertensive pregnancy disorders share
pathophysiology already programmed before the challenge
of pregnancy that ultimately leads to CVD. However, they
also cannot reject the hypothesis that hypertensive preg-
nancy disorders may cause permanent vascular damage
thereby contributing to CVD risk.
Conclusions
Hypertensive pregnancy disorders are associated with an
adverse cardiovascular health profile and an increased risk
of chronic hypertension 6 years after the index pregnancy.
It is important to assess both GH and PE when assessing
chronic hypertension and CVD risks. Women with GH and
PE may be offered long-term cardiovascular follow-up
incorporated in CVD risk management guidelines. BP
profiles measured from early pregnancy onwards might
help to further distinguish women at risk of future chronic
hypertension and CVD.
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